ENDRA Life Sciences Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a net loss of $1.6 million for the quarter, a decrease from a net loss of $2.4 million in the same period last year. For the nine-month period, the company recorded a net loss of $3.9 million, significantly improved from a loss of $7.4 million in the prior year. The reduction in losses is attributed to a 46% decrease in research and development expenses, which totaled $432,113 for the quarter and $1.3 million for the nine months, down from $794,444 and $2.6 million, respectively, in the previous year. This decline reflects the company's shift in focus towards clinical trials and commercialization of its TAEUS technology.
ENDRA's total operating expenses for the third quarter were $1.37 million, down from $1.51 million a year earlier. The company also reported a notable reduction in sales and marketing expenses, which fell by 46% to $45,285 for the quarter, and by 62% to $183,110 for the nine-month period. However, general and administrative expenses increased by 41% to $893,305 for the quarter, primarily due to higher wage-related expenses and stock compensation costs. The company’s cash position decreased to $794,036 as of September 30, 2025, down from $3.2 million at the end of 2024.
In terms of operational developments, ENDRA has not yet generated any revenue from its TAEUS technology, which is designed for accurate liver fat measurement. The company continues to pursue regulatory approvals necessary for commercialization. As part of its strategic initiatives, ENDRA adopted a Digital Asset Treasury (DAT) strategy in 2025, allocating a portion of its treasury reserves to cryptocurrency assets. This strategy aims to enhance liquidity and support ongoing operations, although the company acknowledges the risks associated with cryptocurrency investments.
Looking ahead, ENDRA faces significant financial challenges, with an accumulated deficit of $107.3 million as of September 30, 2025. The company has indicated that it will require additional financing to fund its operations and continue the development of its TAEUS technology. Management is exploring various financing options, including equity sales and potential collaborations, but has not secured any commitments. The company’s ability to continue as a going concern is contingent upon its success in raising sufficient capital to support its business objectives. ENDRA's management has expressed uncertainty regarding the timing and success of its commercialization efforts, emphasizing the need for ongoing funding to navigate its operational and financial landscape.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences develops advanced ultrasound-based platforms, primarily TAEUS, for non-invasive detection and monitoring of liver fat and metabolic diseases. Its core focus is on creating scalable, cost-effective diagnostic tools leveraging thermoacoustic technology, AI integration, and existing ultrasound systems. Serving pharmaceutical, clinical, and medical markets globally, the company aims to improve early diagnosis, disease management, and therapeutic monitoring for conditions like fatty liver disease and obesity.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.